Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Current Assets for 10 consecutive years, with $668.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 59.08% year-over-year to $668.6 million; the trailing twelve-month figure through Jun 2026 stood at $668.6 million (up 59.08% YoY), and the FY2025 full-year result was $527.2 million, up 58.88% from the prior year.
• Current Assets rose to $668.6 million in Q2 2026 per KNSA's latest filing, from $594.2 million in the prior quarter.
• Across five years, Current Assets topped out at $668.6 million in Q2 2026 and bottomed at $179.9 million in Q2 2022.
• Historically, Current Assets has averaged $340.6 million across 5 years, with a median of $288.7 million in 2023.
• The sharpest annual moves came in 2022 and 2026: Current Assets slipped 27.87% in 2022, then jumped 66.95% in 2026.
• Over 5 years, Current Assets stood at $243.1 million in 2022, then rose by 13.67% to $276.3 million in 2023, then gained by 20.09% to $331.8 million in 2024, then surged by 58.88% to $527.2 million in 2025, then grew by 26.83% to $668.6 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $668.6 million, $594.2 million, and $527.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.